Liyuan Hou, Wei Huang, J. Cheng
Nov 5, 2020
Citations
0
Influential Citations
1
Citations
Journal
Chemical communications
Abstract
Here, a triphenylphosphine (TPP)-labile prodrug of seleno-combretastatin-4 (CSeD) was designed and synthesized. A detailed investigation revealed that CSeD, which was shown to be very safe in circulating blood, could react with TPP to release CA-4 and a selenodiazole derivative, with accompanying powerful anticancer and antiangiogenesis effects, as well as radiosensitization properties.